Focusing on the initiation of treatment for newly diagnosed patients with CML, Jorge E. Cortes, MD, details important factors to consider when starting treatment and Claire Saxton discusses strategies ...

EMA committee recommends marketing approval for Novartis’ Scemblix to treat adults with newly diagnosed CML: Basel Monday, October 20, 2025, 11:00 Hrs [IST] Novartis announced t ...

When oral medicines for Chronic Myeloid Leukemia (CML) first became available, they dramatically changed what it meant to ...

If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in EuropeScemblix ...

Dr Lindsay Rein comments on significant advancements in CML treatment presented at ASH 2024, particularly the approval of asciminib in both the frontline and second-line settings. This new treatment ...

The US FDA has accepted the new drug application (NDA) for XS003, a formulation referencing the tyrosine kinase inhibitor (TKI) nilotinib (Tasigna), for treatment of chronic myeloid leukemia (CML). 1 ...

Phyrago is a novel formulation of Sprycel ® (dasatinib) designed to enable concomitant use with proton pump inhibitors (PPIs) and H 2 receptor antagonists (H 2 RAs). 1 Clinical data showed no ...

The survival prognosis for patients with chronic phase CML has greatly improved since the introduction of TKIs, with some studies showing life expectancy close to the general population. Nonetheless, ...

A recent study in the British Journal of Haematology by Irani and colleagues suggests that an effector-suppressor score, which is calculated using absolute natural killer (NK) cell, FoxP3 + regulatory ...

CHICAGO — Asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia, according to study results presented at ASCO ...

Please provide your email address to receive an email when new articles are posted on . In this video, Eric Winer, MD, discusses the results of research into chronic myeloid leukemia presented at ASCO ...